AdvaMed President and CEO Scott Whitaker is leading the call for a reciprocal “zero-for-zero” tariff agreement on medtech, urging the U.S. and its trading partners to eliminate tariffs on essential,…
WASHINGTON – Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today called for a reciprocal “zero for zero” model with respect to tariffs among U.S. trading partners for…
Flexibility on tariffs is critical to maintaining medtech as the backbone of the U.S. health care system and an American economic success story.
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
AdvaMed’s Q1 2025 report focuses on tariffs, policy action, and how we’re protecting Medtech innovation.
WASHINGTON – Today AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker:
Details a sweeping tariff hike to 84% on Chinese imports and de minimis increases, aiming to protect U.S. economic and national security.
Washington, D.C.– AdvaMed®, the Medtech Association, and nine additional organizations urged an exemption from tariffs for medical and dental supplies, equipment, and devices, citing concerns about increased costs resulting in supply…
Washington, D.C.– AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker: “Our country is the birthplace of the medical device and technology industry and leads the…
Tariffs on medical goods threaten healthcare costs, access, and supply chains. Leading health groups urge exemptions to safeguard patient care.